Voyager Therapeutics to Attend Upcoming Investor Conferences
August 12 2016 - 2:15PM
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene
therapy company developing life-changing treatments for severe
diseases of the central nervous system (CNS), today announced that
company management will present at the following upcoming investor
conferences:
- Wedbush PacGrow Healthcare Conference, New York
CityDate: August 16,
2016Time: 9:45 a.m. ETPresenter:
Jeff Goater, chief financial officer
- 2016 Wells Fargo Securities Healthcare Conference,
BostonDate: September 7,
2016Time: 8:45 a.m. ETPresenter:
Steven Paul, MD, president and chief executive officer
Live-streaming webcasts of these presentations
can be accessed through the Investors & Media section of
Voyager’s website at www.voyagertherapeutics.com. The webcast
will be archived for 30 days after the live event concludes.
The Company’s management team will also attend
the following upcoming investor conferences for one-on-one
meetings:
- Citi Annual Biotech Conference,
BostonDate: September 8, 2016
- Morgan Stanley Global Healthcare Conference, New York
CityDate: September 14, 2016
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene
therapy company developing life-changing treatments for severe
diseases of the central nervous system. Voyager is committed
to advancing the field of AAV (adeno-associated virus) gene therapy
through innovation and investment in vector engineering and
optimization, manufacturing and dosing and delivery
techniques. The Company’s pipeline is focused on severe CNS
diseases in need of effective new therapies, including advanced
Parkinson’s disease, a monogenic form of amyotrophic lateral
sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal
muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s
disease and severe, chronic pain. Voyager has broad strategic
collaborations with Sanofi Genzyme, the specialty care global
business unit of Sanofi, and the University of Massachusetts
Medical School. Founded by scientific and clinical leaders in
the fields of AAV gene therapy, expressed RNA interference and
neuroscience, Voyager Therapeutics is headquartered in Cambridge,
Massachusetts. For more information, please visit
www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Investor Relations:
Matt Osborne
Head of Investor Relations & Corporate Communications
857-259-5353
mosborne@vygr.com
Media:
Katie Engleman
Pure Communications, Inc.
910-509-3977
Katie@purecommunicationsinc.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Sep 2023 to Sep 2024